Phenotypic and genotypic characterization of invasive bacterial isolates collected through MLW diagnostic activities from 1996 – 2030
| dc.contributor.author | Cornick, Jennifer | |
| dc.date.accessioned | 2021-12-22T10:28:25Z | |
| dc.date.available | 2021-12-22T10:28:25Z | |
| dc.date.issued | 2020-11-24 | |
| dc.description.abstract | This protocol is a minimally updated version of Protocol P.08/14/1614 which expired on 15/12/2018. Due to increasing rates of drug-resistant infections being observed at Queen Elizabeth Central Hospital in Blantyre, it is important that we resume our phenotypic and genotypic characterization of invasive bacterial isolates collected through Malawi-Liverpool-Wellcome (MLW) Trust diagnostic activities. This audit will allow us to access archived bacterial isolates obtained from routine blood and CSF cultures over a period of more than three decades (1996– 2030). Invasive bacterial infections caused by typhoidal and nontyphoidal Salmonella, Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli and, Klebsiella amongst others, account for high rates of morbidity and mortality in both Malawian children and adults at Queen Elizabeth Central Hospital (QECH). Treatment of bacteraemia and meningitis caused by these bacterial species is made difficult because of increased levels of multiple antibiotic resistant strains. Bacterial surveillance at QECH and MLW in Blantyre began in 1996 and has thus far provided a rich collection of strains that allows phenotypic and genotypic investigations with a historical perspective, data which is used by the Ministry of Health to support its surveillance programmes. Whole genome sequencing has given us novel insights into the epidemiology and mechanisms of antibiotic resistance (AMR) of diverse bacteria that are regionally relevant. For example, WGS gave deep insights into the genetic diversity of S. pneumoniae strains in the era before the introduction of the pneumococcal conjugate vaccine in Malawi, which has been invaluable to support vaccine implementation and to the study of vaccine effectiveness. We have been able to describe increasing antimicrobial resistance rates over the last twenty years amongst key enteric pathogens, with some now locally impossible to treat using first line antibiotics. This audit aims to expand on these achievements by investigating the phenotype and genotype of all the major invasive bacterial isolates at QECH over time. From past experience with stored, frozen samples, it is anticipated that >95% of isolates will be recoverable and the impact on the validity of results obtained would therefore be very limited. Specifically, the audit aims to characterize the type and nature of isolates causing severe bacterial disease in Malawi making use of advanced genotyping and phenotyping techniques, some of which are not yet possible in Malawi. The audit has five main objectives: 1. To perform antimicrobial susceptibility testing to assess AMR rates over time; 2. To perform genotypic characterisation to identify genetic markers of AMR and virulence over time; 3. To employ whole genome sequencing to detect epidemic outbreaks; 4. To perform phenotypic characterization of bacterial isolates to identify the biological mechanisms driving AMR and virulence and to evaluate the efficacy of novel antimicrobials; 5. To build upon existing or develop novel bioinformatic pipelines to analyse bacterial genomic data. The findings will be disseminated among collaborating partners and manuscripts will be prepared for publication in international peer-reviewed journals. A copy of any published paper(s) of the research findings will also be submitted to the College of Medicine Research and Ethics Committee (COMREC), the College of Medicine Research Dissemination Conference, College of Medicine Library, the National Health Sciences Research Committee and the University Research and Publication Committee (URPC) (the latter two through the COMREC Secretariat). As with all our work, with collaborators at the Wellcome Trust Sanger Institute, sequencing will be undertaken free of charge. The number of isolates that can be sequenced each year will be dictated by the Wellcome Trust Sanger Institute sequencing budget. In addition to this, we will actively pursue research funding from national and international funders to prospectively address the objectives outlined in the proposal. At this moment in time, it is however impossible to predict how many samples we will process in total. COMREC overhead costs will therefore be retrospectively calculated based on the number of bacterial isolates | en_US |
| dc.description.sponsorship | The Wellcome Trust Sanger Institute | en_US |
| dc.identifier.uri | http://rscarchive.kuhes.ac.mw/handle/20.500.12988/783 | |
| dc.language.iso | en | en_US |
| dc.publisher | Kamuzu University of Health Sciences | en_US |
| dc.relation.ispartofseries | Protocol;P.06/20/3071 | |
| dc.subject | Research Subject Categories::MEDICINE::Microbiology, immunology, infectious diseases | en_US |
| dc.title | Phenotypic and genotypic characterization of invasive bacterial isolates collected through MLW diagnostic activities from 1996 – 2030 | en_US |
| dc.type | Plan or blueprint | en_US |